№ lp_1_2_32203
File format: docx
Character count: 19761
File size: 81 KB
This document provides an application form to apply for a BCS-based biowaiver to waive bioequivalence studies.
Note:
Year
Topic:
Biopharmaceutics Classification System (BCS)
Document Type:
Application Form
Organization / Institution:
World Health Organization (WHO)
Author:
WHO Prequalification Team: medicines (PQT/MED)
Target Audience:
Applicants seeking a biowaiver for bioequivalence studies
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2017
Region / City:
Global
Topic:
Biopharmaceutics, Drug Classification, Bioequivalence
Document Type:
Assessment Report
Organization / Institution:
IPRP Bioequivalence Working Group for Generics
Author:
BEWGG
Target Audience:
Regulatory authorities, pharmaceutical professionals, drug developers
Period of validity:
Not specified
Approval Date:
10 Feb 2017
Date of amendments:
7 Nov 2024
Year:
2023
Region / city:
Global
Topic:
Biopharmaceutics, Bioequivalence Studies
Document type:
Application Form
Organization / Institution:
World Health Organization (WHO)
Author:
WHO Prequalification Team (PQT/MED)
Target audience:
Applicants seeking BCS-based biowaiver
Period of validity:
N/A
Approval date:
N/A
Amendment date:
N/A
Year:
2017
Region / City:
Global
Topic:
Biopharmaceutics, Drug Classification, Bioequivalence
Document Type:
Assessment Report
Organization / Institution:
IPRP Bioequivalence Working Group for Generics
Author:
BEWGG
Target Audience:
Regulatory authorities, pharmaceutical professionals, drug developers
Period of validity:
Not specified
Approval Date:
10 Feb 2017
Date of amendments:
7 Nov 2024
Year:
2017
Region / City:
N/A
Theme:
Biowaiver application
Document Type:
Application Form
Organization / Institution:
WHO
Author:
N/A
Target Audience:
Pharmaceutical applicants
Period of Validity:
N/A
Approval Date:
N/A
Date of Amendments:
N/A
Year:
2023
Region / city:
Global
Topic:
Biopharmaceutics, Bioequivalence Studies
Document type:
Application Form
Organization / Institution:
World Health Organization (WHO)
Author:
WHO Prequalification Team (PQT/MED)
Target audience:
Applicants seeking BCS-based biowaiver
Period of validity:
N/A
Approval date:
N/A
Amendment date:
N/A
Note:
Year
Topic:
Biopharmaceutics
Document Type:
Biowaiver Information Form
Institution:
MCAZ
Target Audience:
Applicants seeking a BCS-based biowaiver
Year:
2023
Region / City:
United Kingdom
Theme:
Legal Agreement
Document Type:
Master Services Agreement
Organization / Institution:
BCS (British Computer Society)
Author:
BCS Group
Target Audience:
Clients of BCS Group
Effective Date:
As per signed Order Form
Date of Approval:
Not specified
Date of Changes:
Not specified
Note:
Year
Topic:
Professional certification
Document type:
Application form
Organization:
BCS (British Computer Society)
Target audience:
Professionals seeking BCS Fellowship
Year:
2017
Region / City:
Global
Topic:
Biopharmaceutics, Drug Classification, Bioequivalence
Document Type:
Assessment Report
Organization / Institution:
IPRP Bioequivalence Working Group for Generics
Author:
BEWGG
Target Audience:
Regulatory authorities, pharmaceutical professionals, drug developers
Period of validity:
Not specified
Approval Date:
10 Feb 2017
Date of amendments:
7 Nov 2024
Year:
2026
Region / City:
Not specified
Topic:
Professional Project in IT
Document Type:
Submission Form
Organization / Institution:
BCS (British Computer Society)
Author:
Not specified
Target Audience:
Candidates for BCS Higher Education Qualifications
Period of validity:
Not specified
Approval Date:
Not specified
Modification Date:
Not specified
Year:
2023
Region / city:
Global
Topic:
Biopharmaceutics, Bioequivalence Studies
Document type:
Application Form
Organization / Institution:
World Health Organization (WHO)
Author:
WHO Prequalification Team (PQT/MED)
Target audience:
Applicants seeking BCS-based biowaiver
Period of validity:
N/A
Approval date:
N/A
Amendment date:
N/A
Year:
2022
Region / City:
British Columbia
Theme:
Digital Learning, Post-Secondary Education
Document Type:
Strategy Report
Organization:
Ministry of Post-Secondary Education and Future Skills (PSFS)
Author:
Digital Learning Advisory Committee (DLAC)
Target Audience:
Post-secondary institutions, educators, learners, Indigenous communities
Period of Validity:
2022–2027
Approval Date:
March 2022
Amendment Date:
Not specified
Year:
2026
Region / City:
United Kingdom
Topic:
Health and Care Informatics, Strategy, Policy
Document Type:
Job Description / Role Outline
Organization:
BCS, The Chartered Institute for IT
Author:
BCS Human Resources
Target Audience:
Health and care informatics professionals, potential volunteers
Responsibilities:
Develop and coordinate strategic objectives and policy priorities, represent informatics profession, support BCS growth
Skills Required:
Leadership, communication, policy understanding, networking, digital tools proficiency
Volunteering Opportunities:
Yes, locally and nationally
Diversity and Inclusion:
Encouraged applications from under-represented groups
Commitment:
Attendance at meetings, completion of assigned tasks
Note:
Year
Topic:
Biopharmaceutics
Document Type:
Biowaiver Information Form
Institution:
MCAZ
Target Audience:
Applicants seeking a BCS-based biowaiver
Year:
2026
Location:
Gothenburg, Sweden
Subject:
5G NR Carrier Aggregation Technical Report
Document Type:
Technical Paper (TP)
Organization:
3GPP TSG-RAN WG4
Authors:
Nokia, Verizon
Intended Audience:
3GPP Working Group Members
Agenda Item:
5.6.3
Purpose:
Approval
Frequency Bands:
n13, n77
Channel Bandwidths:
Detailed per CA configuration
Harmonics and Intermodulation Analysis:
Included
Cross-band Isolation:
Analyzed